|Table of Contents|

Comparative analysis of the incidence and efficacy of invasive pulmonary fungal infection in solid malignant tumors and hematological tumors

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2021 03
Page:
503-507
Research Field:
Publishing date:

Info

Title:
Comparative analysis of the incidence and efficacy of invasive pulmonary fungal infection in solid malignant tumors and hematological tumors
Author(s):
WANG Yueqiao1; 2; GUO Zhi2; LI Shuluan3; XIE Jing2; LIU Xuanyong2; CHEN Lina2; LAN Xiaofeng3; LAN Dongmei3; JIN Chuan1
1.Guangzhou Medical University，Guangdong Guangzhou 511436，China；2.Department of Hematology ＆ Oncology；3.Department of Oncology，National Cancer Center/National Clinical Research Cancer for Cancer/Cancer Hospital ＆ Shenzhen Hosptial，Chinese Academy of Medical Sciences and Peking Union Medical College，Guangdong Shenzhen 518116，China.
Keywords:
invasive pulmonary fungal infection; solid malignant tumors; hematological tumors; antifungal therapy
PACS:
R730
DOI:
DOI：10.3969/j.issn.1672-4992.2021.03.031
Abstract:
Objective：To compare and analyze the incidence，risk factors，clinical features and antifungal treatment results of invasive pulmonary fungal infection(IPFI) in patients with solid malignant tumors and hematological tumors，to improve the understanding of diagnosis and treatment of invasive pulmonary fungal infections.Methods：We retrospectively analyzed clinical data of patients with solid malignant tumors or hematological tumors with invasive pulmonary fungal infection and antifungal treatment from June 2017 to June 2019，Shenzhen Hospital of the Chinese Academy of Medical Sciences Cancer Hospital.We compared risk factors，clinical characteristics，response rate to antifungal therapy，and median time to medication between the two groups.Results：There were 30 patients with solid malignant tumors combined with IPFI，and the incidence rate was 0.42%.There were 228 patients with hematological tumors combined with IPFI，and the incidence rate was 10.6%.The difference was statistically significant(P<0.05).The proportion of males in the solid malignant tumor group were 33.3%(10/30).The proportion of males in the hematological tumor group were 61.4%(140/228).Multivariate analysis showed statistically significant differences in neutrophihic status，history of steroid therapy，history of diabetes，history of chronic lung disease，symptoms of cough and sputum，positive rate of G/GM test，and positive rate of microbial culture.There were no significant differences between the two group in age above 65 years，fever，dyspnea，and characteristic imaging features of the lungs.The proportion of combined antifungal therapy in the hematological tumor group was 35.1%(80/228)，but not in the solid malignant tumor group.The median treatment time in the two groups was 17.89±7.738 days and 13.55±5.176 days，and the total effective rate was 61.5%(91/148) and 75%(60/80).The difference was statistically significant(P<0.05).Conclusion：Invasive pulmonary fungal infections have higher incidence in patients with hematological tumors.The efficacy of hematological tumors combined with antifungal therapy is accurate and safe，which deserves further clinical application in solid malignancies.

References:

[1]COLOMBO AL，DE ALMEIDA JNIOR JN，SLAVIN MA，et al.Candida and invasive mould diseases in non-neutropenic critically ill patients and patients with haematological cancer［J］.Lancet Infect Dis，2017，17(11)：e344-356.
[2]GUO Z，GAO HY，ZHANG TY，et al.Analysis of allogeneic hematopoietic stem cell transplantation with high-dose cyclophosphamide-induced immune tolerance for severe aplastic anemia［J］.Int J Hematol，2016，104(6)：720-728.
[3]张雪云，刘晓东，史志勇，等.急性白血病移植后合并肺部真菌感染的临床分析［J］.肿瘤预防与治疗，2018，31(3)：178-182. ZHANG XY，LIU XD，SHI ZY，et al.Clinical analysis of pulmonary fungal infection after transplantation for acute leukemia［J］.Cancer Control Treat，2018，31(3)：178-182.
[4] 《抗菌药物临床试验技术指导原则》写作组.抗菌药物临床试验技术指导原则［J］.中国临床药理学杂志，2014，30(9)：844-856. Writing Group of Guidance for Clinical Trials of Anti-Bacterial Drugs.Guidance for clinical trials of anti-bacterial drugs［J］.Chin J Clin Pharmacol，2014，30(9)：844-856.
[5] 中国侵袭性真菌感染工作组.血液病/恶性肿瘤患者侵袭性真菌病的诊断标准与治疗原则(第五次修订版)［J］.中华内科杂志，2017，56(6)：453-459. Chinese Invasive Fungal Infection Working Group.The Chinese guidelines for the diagnosis and treatment of invasive fungal disease in patients with hematological disorders and cancers（the fifth revision）［J］.Chin J Intern Med，2017，56(6)：453-459.
[6]GARNICA M，DA CUNHA MO，PORTUGAL R，et al.Risk factors for invasive fusariosis in patients with acute myeloid leukemia and in hematopoietic cell transplant recipients［J］.Clin Infect Dis，2015，60(6)：875-880.
[7]刘荣华，关丽，张亚庆，等.恶性肿瘤患者侵袭性真菌感染危险因素分析［J］.现代肿瘤医学，2015，23(22)：3344-3346. LIU RH，GUAN L，ZHANG YQ，et al.Risk factors of invasive fungal infections in malignant tumor patients［J］.Modern Oncology，2015，23(22)：3344-3346.
[8]郭智，任骅，胡亮钉，等.重型再生障碍性贫血移植后合并侵袭性肺部真菌感染6例临床分析［J］.解放军医学杂志，2017，42(12)：1097-1101. GUO Z，REN H，HU LD，et al.Clinical research of severe aplastic anemia with pulmonary invasive fungal infection after transplantation［J］.Med J Chin PLA，2017，42(12)：1097-1101.
[9]DANDACHI D，WILSON DR，FERNNDEZ-CRUZ A，et al.Invasive pulmonary aspergillosis in patients with solid tumours：Risk factors and predictors of clinical outcomes［J］.Ann Med，2018，50(8)：713-720.
[10] LIEN MY，CHOU CH，LIN CC，et al.Epidemiology and risk factors for invasive fungal infections during induction chemotherapy for newly diagnosed acute myeloid leukemia：A retrospective cohort study［J］.PLoS One，2018，13(6)：e0197851.
[11]GUITARD J，TABONE MD，SENGHOR Y，et al.Detection of β-D-glucan for the diagnosis of invasive fungal infection in children with hematological malignancy［J］.J Infect，2016，73(6)：607-615.
[12]GUPTA P，AHMAD A，KHARE V，et al.Comparative evaluation of pan-fungal real-time PCR，galactomannan and(1-3)-β-D-glucan assay for invasive fungal infection in paediatric cancer patients［J］.Mycoses，2017，60(4)：234-240.
[13] 张海涛，郝锦霞，郭桂丽.G试验联合GM试验在恶性血液病侵袭性真菌感染的诊断价值［J］.现代肿瘤医学，2012，20(10)：2161-2163. ZHANG HT，HAO JX，GUO GL.Risk factors of invasive fungal infections in malignant tumor patients［J］.Modern Oncology，2012，20(10)：2161-2163.
[14]SANO H，KOBAYASHI R，HORI D，et al.Prophylactic administration of voriconazole with two different doses for invasive fungal infection in children and adolescents with acute myeloid leukemia［J］.J Microbiol Immunol Infect，2018，51(2)：260-266.
[15] OKAMOTO T，KOH K，TAKITA J，et al.Voriconazole-micafungin combination therapy for acute lymphoblastic leukemia［J］.Pediatr Int，2010，52(1)：137-141.
[16] SHANG W，FENG G，SUN R，et al.Comparison of micafungin and voriconazole in the treatment of invasive fungal infections in kidney transplant recipients［J］.J Clin Pharm Ther，2012，37(6)：652-656.

Memo

Memo:
深圳市卫生系统科研项目（编号：SZLY2018003)
Last Update: 2021-01-02